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Hematopoietic stem cell transplantation in Europe 2014: more
than 40000 transplants annually
JR Passweg1, H Baldomero1, P Bader2, C Bonini3, S Cesaro4, P Dreger5, RF Duarte6, C Dufour7, J Kuball8, D Farge-Bancel9, A Gennery10,
N Kröger11, F Lanza12, A Nagler13, A Sureda6 and M Mohty14 for the European Society for Blood and Marrow Transplantation (EBMT)
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704
autologous (57%)) were reported by 656 centers in 47 countries to the 2014 survey. Trends include: continued growth in transplant
activity, more so in Eastern European countries than in the west; a continued increase in the use of haploidentical family donors (by
25%) and slower growth for unrelated donor HSCT. The use of cord blood as a stem cell source has decreased again in 2014. Main
indications for HSCT were leukemias: 11 853 (33%; 96% allogeneic); lymphoid neoplasias; 20 802 (57%; 11% allogeneic); solid
tumors; 1458 (4%; 3% allogeneic) and non-malignant disorders; 2203 (6%; 88% allogeneic). Changes in transplant activity include
more allogeneic HSCT for AML in CR1, myeloproliferative neoplasm (MPN) and aplastic anemia and decreasing use in CLL; and more
autologous HSCT for plasma cell disorders and in particular for amyloidosis. In addition, data on numbers of teams doing alternative
donor transplants, allogeneic after autologous HSCT, autologous cord blood transplants are presented.
Bone Marrow Transplantation advance online publication, 22 February 2016; doi:10.1038/bmt.2016.20
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is an established
procedure for many acquired and congenital disorders of the
hematopoietic system, including disorders of the immune
system, and as enzyme replacement in metabolic disorders.1–4
The annual activity survey of the European Society of Blood and
Marrow Transplantation (EBMT), describing the status
of HSCT in Europe and affiliated countries, has become an
instrument used to observe trends and to monitor changes in
technology use.5–12 The survey captures the numbers of HSCT
performed in the preceding year from each participating
team, divided by indication, donor type and stem cell source.
The standardized structure of the survey over many
years and the excellent commitment of the participating teams
allow us to observe changes over time and to evaluate
factors associated with these changes. More recently, the survey
has included additional information on novel cell therapies with
hematopoietic stem cells for non-hematopoietic use, as
well as on the use of non-hematopoietic stem and progenitor
cells. This coincides with the recent interest of the World
Health Organization (WHO) (www.who.org) in cell and tissue
transplants, and further stresses the need for adequate and
timely information.13 The analysis of the survey data spanning
over 20 years has shown a continued and constant increase
in the annual numbers of HSCT and transplant rates (number of
HSCT per 10 million inhabitants) for both allogeneic and
autologous HSCT.
This report is based on the 2014 survey data. In addition to
transplant rates and indications, this report focuses on the use of
donors other than HLA identical siblings and matched unrelated
donors for allogeneic HSCT.
PATIENTS AND METHODS
Data collection and validation
Participating teams were invited to report data for 2014 by indication, stem
cell source and donor type as listed in Table 1. The survey allows the
possibility to report additional information on the numbers of subsequent
transplants performed as a result of relapse, rejection or those that are part
of a planned sequential transplant protocol. Supplementary information
on the numbers of donor lymphocyte infusions, reduced intensity HSCT
and the numbers of pediatric HSCT is also collected. Quality control
measures included several independent systems: confirmation of validity
of the entered data by the reporting team, selective comparison of the
survey data with MED-A data sets in the EBMT Registry database and
cross-checking with the National Registries.
Teams
In all, 680 centers from 49 countries were contacted for the 2014 survey
(40 European and 9 affiliated countries); of which 656 teams reported. This
corresponds to a 97% return rate and includes 553 active EBMT member
teams. Twenty-six active teams failed to report in 2014.
Contacted teams are listed in the Supplementary information in
alphabetical order by country, city, EBMT centre code, with their reported
numbers of first and total HSCT, and of first allogeneic and autologous
HSCT. The WHO regional office definitions (www.who.org) were used to
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classify countries as European or Non-European. Nine non-European
countries participated in the 2014 EBMT survey: Algeria, Iran, Israel, Jordan,
Lebanon, Nigeria, Saudi Arabia, South Africa and Tunisia. Their data
(2716 HSCT) from 30 actively transplanting teams makes up 6.7% of the
total data set and are included in all analyses.
Patient and transplant numbers
Wherever appropriate, patient numbers corresponding to the number of
patients receiving a first transplant and transplant numbers reflecting the
total number of transplants performed are listed.
The term sibling donor includes HLA identical siblings and twins but not
siblings with HLA mismatches. Unrelated donor transplants include HSCT
from unrelated donors with peripheral blood and marrow as a stem cell
source but not cord blood HSCT, these are shown as cord blood HSCT in
Figure 3a. Mismatched family donors are termed ‘haploidentical’ for the
purpose of this analysis, but this category includes also mismatched
related donors that are mismatched to a lesser degree than a full
haplotype. As the haplotype mismatched donors are the majority in this
category, the term ‘haploidentical’ is used for the entire group.
Multiple transplants may include multiple transplants defined as
subsequent transplants within a planned double or triple autologous
or allogeneic transplant protocol, and retransplants (autologous or
allogeneic) defined as unplanned HSCT for rejection or relapse after a
previous HSCT.
Transplant rates
Transplant rates, defined as the total number of HSCT per 10 million
inhabitants, were computed for each country without adjustments for
patients who crossed borders and received their HSCT in a foreign country.
Population numbers were obtained from Eurostats for 2014 for the
European countries (http://epp.eurostat.ec.europa.eu/portal/page/portal/




Wherever appropriate absolute numbers of transplanted patients, trans-




Participating teams in 2014. Of the 656 teams, 410 (62%)
performed both allogeneic and autologous transplants; 227
(35%) restricted their activity to autologous HSCT, and 13 teams
(2%) to allogeneic transplants only. Six teams (1%) reported
having performed no transplants in 2014 due to renovation or
temporary closure of the transplant unit. Of the 656 active centers,
118 (18%) centers performed transplants on both adult and
pediatric patients. An additional 107 (16%) centers were dedicated
pediatric transplant centers and 431 (66%) centers performed
transplants on adults only.
Numbers of patients and transplants. In 2014, 40 829 transplants
were reported in 36 469 patients (first transplant) increasing the
number of transplants to over 40 000 for the first time since 1990.
Of these, 16 946 (42%) were allogeneic; 23 883 (58%) were
autologous. When compared with 2013, the total number of
transplants increased by 4.1% (4.5% allogeneic HSCT and 3.8%
autologous HSCT).11 Furthermore, there were 4360 second or
subsequent transplants 1181 allogeneic and 3179 autologous. The
total number of transplants increased by 22% compared with
5 years (since 2010) and 80% compared with 15 years (2000)
previously. The total number of patients transplanted under the
age of 18 in both dedicated and joint adult-pediatric units was
4400 (3279 allogeneic and 1121 autologous HSCT). Of these, 3117
patients (71%) (2420 allogenic and 697 autologous) were
performed in dedicated pediatric centers.
Indications. Indications for HSCT in 2014 are listed in detail in
Table 1. Main indications were leukemia’s (including primarily
AML, ALL and myelodysplastic syndrome (MDS)/myelodysplastic
(MD)/myeloproliferative neoplasm (MPN)): 11 853 (33% of total;
96% of which were allogeneic); lymphoid neoplasias including
non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma and plasma
cell disorders: 20 802 (57%; 11% allogeneic); solid tumors: 1458
(4%; 3% allogeneic); and non-malignant disorders; 2203 (6%; 88%
allogeneic). As seen in previous years, the majority of HSCT for
lymphoid malignancies were autologous while most transplants
for leukemia were performed using stem cells from allogeneic
donors. Autologous HSCT for non-malignant disorders predomi-
nantly include patients with autoimmune disorders (Figures 1a
and b). For the first time since 1990 450% of patients receiving
autologous HSCT had plasma cell disorders (Figure 1b).
Distributions of indications for HSCT are shown in Figures 1a
and b for allogeneic and autologous HSCT, respectively. Compared
with 2013, there were increases in allogeneic HSCT for AML in CR1
by 13%, myeloproliferative neoplasm 14% and severe aplastic































Figure 1. Relative proportions of indications for an HSCT in Europe in 2014. (a) Proportions of disease indications for an allogeneic HSCT in
Europe in 2014. (b) Proportions of disease indications for an autologous HSCT in Europe in 2014.
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anemia (SAA) by 12%. A decrease was seen in CLL by 21%. For
autologous HSCT, there was an increase in myeloma by 5%,
amyloidosis by 44% (N= 114), Hodgkin's lymphoma by 8% and
autoimmune disease by 40%. No major decrease in activity was
seen for any given disease. In all, 2649 patients received treatment
with donor lymphocyte infusions, a 5.4% increase since 2013. In
all, 6871 of the total allogeneic HSCT were performed using non-
myeloablative conditioning. This is an increase of 5.2% since in
2014 and is 41% of all allogeneic HSCT.
Transplant rates. Figures 2a and b show transplant rates by country
for allogeneic and autologous HSCT comparing rates in 2014. Median
transplant rates per 10 million inhabitants were 133 (range, 5.2–495)
for allogeneic HSCT and 230 (range, 9.5–530) for autologous HSCT in
2014. As shown in Figure 3a, numbers of allogeneic HSCT continue to
increase, more in unrelated donor HSCT than in sibling HSCT, while
cord blood transplants are slightly decreasing. There is a significant
increase in transplants from haploidentical donors and it appears that
this comes at the expense of a slower increase in the use of
unrelated donors and cord blood.14–16
As these transplants are done by dedicated teams, Figure 3b
shows the development of the number of teams since 1990
reporting any type of HSCT. The figure shows that the increase in
haploidentical HSCT is paralleled by the number of teams
performing these types of HSCT and similarly a lower number of
teams reporting cord blood HSCT in 2014.
N. allogeneic transplants 2014  
per 10 million population
per 10 million population
0 or no report
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Figure 2. Transplant rates in Europe (= total number of HSCT per 10 million inhabitants) by participating country in 2014. (a) Allogeneic
transplant rates per 10 million population in 2014. (b) Autologous transplant rates per 10 million population in 2014.
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The activity survey has collected data on allogeneic HSCT in
patients having had a prior autologous HSCT either planned
or to treat relapse. Figure 4 shows 566 allogeneic transplants after
an autograft treatment protocol. The main indications were
myeloma (39% N= 223), NHL (30% N= 171) and Hodgkin's
lymphoma (20% N= 114). The numbers have remained more or
less stable over the last 10 years.
Autologous cord blood transplantation. Information on cord
blood transplants has been collected since this stem cell source
was introduced in 1997. As numerous autologous cord blood
banks exist, the use of autologous cord blood is of interest.17 We
found since 2007 a small number of confirmed autologous cord
blood HSCT. The main indication was SAA (N= 6) followed by NHL
(N= 3), neuroblastoma (N= 3), MDS (N= 2), MPN (N= 1) and other
solid tumor (N= 1).
Evolving countries. HSCT activity is increasing in many countries;
in some countries, this increase was particularly striking; in
particular a clear growth in transplant activity in countries of
Eastern Europe can be seen. Figures 5a and b show increases in %
of allogeneic and autologous transplant activity respectively since
2004, that is, for the last 10 years in all countries reporting 4100
HSCT in 2014. The greatest increase was seen for allogeneic HSCT
in Romania, Russia, Turkey, Croatia, Lithuania and Serbia (ranging
from 1000% to 4200%, respectively) and for autologous HSCT in
Romania, Serbia, Russia, Turkey and Iran (ranging from 1200% to
4200%, respectively).
Additional cellular therapies. In all, 15 teams from 11 countries
reported through the activity survey the treatment of 160
patients with hematopoietic stem cells for non-hematopoietic
use in 2014. A total of 152 therapies were performed using
autologous HSCs with 8 using allogeneic HSCs for epithelial
diseases. The main indications were cardiovascular, 88; neurolo-
gical, 47; tissue repair, 17 and epithelial: 8. In addition, 525
patients in 93 teams and 20 countries received mesenchymal
stromal cells for prevention/treatment of GvHD (450, increasing
from 213 in 2010 and 344 in 2013), prevention/treatment of graft
failure (27) and for unspecified reasons (48; 38 of which were
allogeneic).
DISCUSSION
The EBMT activity survey has been conducted annually since
1990.6 The 2010 survey reported for the first time more than
30 000 patients transplanted in a given year,18 this is now
followed by 440 000 transplants in this 2014 survey. Therefore,
transplant numbers continue to increase unabated.
HSCT for some indications continues to increase but not for
others. Of interest is growth of allogeneic HSCT for AML in CR1,
myeloproliferative neoplasia and marrow failure and a notable
decrease in CLL possibly due to the availability of novel kinase
inhibitors. In autologous HSCT, transplant activity in myeloma
continues to increase and in particular in amyloidosis possibly
following publication of positive results.19
In allogeneic HSCT, the use of unrelated donors continues to
increase but less so than in previous years (median 12% annual
increase in the years 2004–2010 and 5% annual increase in the
years 2011–2014). This is compensated for by an increase in the
use of haploidentical donors, who are in some sense competition
for unrelated and cord blood transplants (median 2% annual
increase in the years 2004–2010 and 25% annual increase in the
years 2011–2014).
In this year's survey, we looked at the number of teams
performing these particular transplants and activity in unrelated
donor cord blood HSCT and haploidentical HSCTs mirrors the
transplant activity for these particular indications, that is, more
haploidentical HSCTs are also performed by more teams doing
haploidentical HSCT.
We looked for the first time at allogeneic HSCTs done after
autologous HSCTs. The majority of these transplants are for
myeloma, non-Hodgkin lymphoma and Hodgkin's lymphoma
showing that probably the majority of this activity reflects salvage
allogeneic procedures after failed autologous HSCT.
Transplant activity is distributed unevenly throughout Europe,
and several analyses have shown correlation with income. As
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Figure 3. Numbers of HSCT and teams by transplant and donor type
1990–2014. (a) Absolute numbers of sibling, haploidentical, cord
blood and unrelated donors HSCT in Europe 1990–2014. (b) Number
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Figure 4. Main indication for allogeneic HSCT after a previous
autologous HSCT in Europe since 2004.
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autologous HSCT are in middle income countries, particularly in
Eastern Europe who are catching up with Western European
countries.
We have added a paragraph on the use of autologous cord
blood transplantation. These cord blood products were most
certainly retrieved from private autologous cord blood banks.17
The largest indication was for marrow failure. The numbers
shown here, that is, slightly more than two procedures per year
reflect the rare indications for such transplants and may fuel the
discussion on the usefulness of autologous cord blood banks in
Europe.
In conclusion, this year's activity survey shows a continued
increase in the use of HSCT across Europe. Some trends are visible
and are discussed here. The paper reflects current practice and
results may be useful to health-care planning and health policy
makers.
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Figure 5. Percentage increase in HSCT activity between the years 2004 and 2014 in countries reporting 4100 HSCT in 2014. (a) Increase in
allogeneic HSCT. (b) Increase in autologous HSCT.
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